Patterson BJ, Buck PO, Curran D, Van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021 May 26;5(3):596-604. doi: 10.1016/j.mayocpiqo.2021.03.006
Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A, Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review. Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671
Karanth S, Rajan SS, Sharma G, Yamal JM, Morgan RO. Racial-ethnic disparities in end-of-life care quality among lung cancer patients: a SEER-medicare-based study. J Thorac Oncol. 2018 Aug;13(8):1083-93. doi: 10.1016/j.jtho.2018.04.014
Margulis AV, Houben E, Hallas J, Overbeek JA, Pottegard A, Torp-Pedersen T, Perez-Gutthann S, Arana A. Ophthalmic nepafenac use in the Netherlands and Denmark. Acta Ophthalmol. 2017 Aug;95(5):509-17. doi: 10.1111/aos.13468
Groenwold R, Uddin M, Roes K, de Boer A, Rivero-Ferrer E, Martin E, Gatto N, Klungel O. Instrumental variable analysis in randomized trials with non-compliance and observational pharmacoepidemiologic studies. OA Epidemiology. 2014 May 9;2(1):9.
Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, Greco FA. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol. 2014;19(3):479-84. doi: 10.1007/s10147-013-0583-0